OctoPlus Wins New Drug Delivery Evaluation Contract
News Apr 06, 2009
As part of the Company's strategic focus on developing controlled release formulations for clients, OctoPlus N.V. announces that it has signed a new drug delivery technology evaluation contract with a European biotech company. This is the seventh client for which OctoPlus will work on a controlled release formulation.
In October last year OctoPlus announced a strategic focus on developing controlled release versions of existing or new drugs for clients, in addition to providing general formulation development and clinical material manufacturing.
Under the contract, OctoPlus will evaluate the feasibility of a controlled release formulation that combines the active ingredient of the client with OctoPlus' proprietary drug delivery technology. If the evaluation is successful, the contract may progress to a full process development, manufacturing and licensing agreement.
Hits for a Novel Drug Target Identified for Depression and PainNews
Novel small molecules have been identified that might be transformed into a new medical treatment of depression and/or even the potential in the treatment of pain.READ MORE
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE
Flow Chemistry Process Development: Johnson Matthey and Snapdragon Chemistry Announce PartnershipNews
Johnson Matthey and Snapdragon Chemistry Inc. are pleased to announce that they have entered in to a collaborative agreement to provide integrated continuous manufacturing services – from development to full-scale GMP manufacturing.READ MORE